|
Schizophrenia
|
0.320 |
Biomarker
|
disease |
BEFREE |
We tested 392 patients with schizophrenia or schizoaffective disorder and 226 healthy normal volunteers for association with NEUROG1.
|
18799289 |
2008 |
|
Schizophrenia
|
0.320 |
Biomarker
|
disease |
PSYGENET |
We tested 392 patients with schizophrenia or schizoaffective disorder and 226 healthy normal volunteers for association with NEUROG1.
|
18799289 |
2008 |
|
Schizophrenia
|
0.320 |
GeneticVariation
|
disease |
LHGDN |
We sequenced neurog1 in 25 affected subjects from the Irish Study of High-Density Schizophrenia Families.
|
17044100 |
2007 |
|
Schizophrenia
|
0.320 |
Biomarker
|
disease |
BEFREE |
We sequenced neurog1 in 25 affected subjects from the Irish Study of High-Density Schizophrenia Families.
|
17044100 |
2007 |
|
Schizophrenia
|
0.320 |
Biomarker
|
disease |
PSYGENET |
We sequenced neurog1 in 25 affected subjects from the Irish Study of High-Density Schizophrenia Families.
|
17044100 |
2007 |
|
Schizoaffective Disorder
|
0.310 |
Biomarker
|
disease |
PSYGENET |
We tested 392 patients with schizophrenia or schizoaffective disorder and 226 healthy normal volunteers for association with NEUROG1.
|
18799289 |
2008 |
|
Schizoaffective Disorder
|
0.310 |
Biomarker
|
disease |
BEFREE |
We tested 392 patients with schizophrenia or schizoaffective disorder and 226 healthy normal volunteers for association with NEUROG1.
|
18799289 |
2008 |
|
Medulloblastoma
|
0.050 |
Biomarker
|
disease |
BEFREE |
Other important effectors of RalA pathway including RalA binding protein-1 (RalBP1) and protein phosphatase A (PP2A) down-stream of Ral and Aurora kinase A (AKA) as an upstream RalA activator were also investigated in MDB.
|
27566179 |
2016 |
|
Medulloblastoma
|
0.050 |
AlteredExpression
|
disease |
BEFREE |
We found that the transcription factor NEUROG1 (but not ATOH1) is expressed in cLPN, unlike normal adult cerebellum, and that fatty acid binding protein 4 (FABP4), typically found in adipocytes, is significantly overexpressed compared with both normal adult cerebellum and human MB.
|
22476608 |
2012 |
|
Medulloblastoma
|
0.050 |
AlteredExpression
|
disease |
BEFREE |
Supratentorial PNETs expressed significantly higher levels of SOX2, NOTCH1, ID1, and ASCL-1 transcripts, whereas the transcription of proneural basic helix-loop-helix factors, NEUROD1, NEUROG1 (significantly), and NEUROG2 (not significantly) was upregulated in medulloblastomas.
|
20515335 |
2010 |
|
Medulloblastoma
|
0.050 |
AlteredExpression
|
disease |
BEFREE |
The mRNA expression of NEUROG1 and Ngn1 was selectively found in medulloblastomas not expressing ATOH1 and in progenitors of the cerebellar ventricular zone, respectively.
|
17522332 |
2007 |
|
Medulloblastoma
|
0.050 |
AlteredExpression
|
disease |
BEFREE |
NEUROD1 was expressed in each of the 12 medulloblastoma specimens, whereas NEUROD2 and NEUROD3/neurogenin were expressed in partly overlapping subsets of medulloblastomas.
|
9270024 |
1997 |
|
Colorectal Carcinoma
|
0.040 |
PosttranslationalModification
|
disease |
BEFREE |
In conclusion, concurrent methylation of NEUROG1 and CDKN2A (p16) is associated with recurrence following adjuvant FOLFOX in Stages II/III colorectal cancer.
|
23034738 |
2013 |
|
Colorectal Carcinoma
|
0.040 |
PosttranslationalModification
|
disease |
BEFREE |
The aim of the present study was to examine the presence of DNA sequences of five human DNA viruses (assessed by PCR): JC polyoma virus (JCV), human adenovirus (AdV), Epstein-Barr virus (EBV), Kaposi sarcoma-associated herpesvirus (KSHV/HHV8) and human papillomavirus (HPV) in a cohort of 186 sporadic colorectal cancers (CRCs) and related these data with the methylation status of six CpG island methylator phenotype (CIMP)-specific genes (MLH1, CACNA1G, NEUROG1, IGF2, SOCS1, RUNX3) and seven cancer-related genes markers (p16, MINT1, MINT2, MINT31, EN1, SCTR and INHBB) assessed by methylation-specific PCR in 186 and 134 CRC cases, respectively.
|
21625944 |
2011 |
|
Colorectal Carcinoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
At a specificity of 91%, NEUROG1 reached a sensitivity of 61% (confidence interval, 50.4-70.6%) for the detection of colorectal cancers.
|
21326223 |
2011 |
|
Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
Methylation of the NEUROG1 gene is frequently found in sera of patients with colorectal cancers independent of tumor stage.
|
21326223 |
2011 |
|
Colorectal Carcinoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
We developed quantitative real time polymerase chain reaction (MethyLight) assays and measured DNA methylation (percentage of methylated reference) of five carefully selected loci (promoters of CACNA1G, CDKN2A (p16), CRABP1, MLH1, and NEUROG1) in 460 colorectal cancers from large prospective cohorts.
|
16407376 |
2006 |
|
Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
Utilizing real-time PCR (MethyLight), we quantified DNA methylation in five CIMP-specific gene promoters [CACNA1G (calcium channel, voltage-dependent, T type alpha-1G subunit), CDKN2A (p16/INK4A), CRABP1 (cellular retinoic acid binding protein-1), MLH1 and NEUROG1 (neurogenin 1)] and MGMT in six synchronous carcinoma pairs (12 carcinomas) and eight synchronous carcinoma and adenoma pairs (16 tumors).
|
16699497 |
2006 |
|
Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
Using MethyLight, we measured DNA methylation in five CIMP-specific gene promoters [CACNA1G, CDKN2A (p16/INK4A), CRABP1, MLH1, and NEUROG1] in relatively unbiased samples of 751 colorectal cancer cases obtained from two large prospective cohorts; 115 (15%) tumors were CIMP-high (> or = 4 of 5 methylated promoters), 251 (33%) were CIMP-low (1 to 3 methylated promoters), and the remaining 385 (51%) were CIMP-0 (no methylated promoters).
|
16820091 |
2006 |
|
Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
The only other NEUROD3-positive tumor progressed early in treatment.
|
9270024 |
1997 |
|
Malignant neoplasm of colon and/or rectum
|
0.020 |
PosttranslationalModification
|
disease |
BEFREE |
In conclusion, concurrent methylation of NEUROG1 and CDKN2A (p16) is associated with recurrence following adjuvant FOLFOX in Stages II/III colorectal cancer.
|
23034738 |
2013 |
|
Malignant neoplasm of colon and/or rectum
|
0.020 |
Biomarker
|
disease |
BEFREE |
Compared with other methylation markers, such as ALX4, SEPT9, and vimentin, NEUROG1 shows a higher sensitivity for colorectal cancer at UICC stages I and II.
|
21326223 |
2011 |
|
Glomerulonephritis
|
0.010 |
Biomarker
|
disease |
BEFREE |
UF-%sRBCs, %dRBCs, urine protein, serum creatinine, and estimated-glomerular filtration rate differed between the GN and NGN groups, with the greatest differences detected for UF-%sRBCs and %dRBCs (<i>P</i><0.0001).
|
30623619 |
2019 |
|
Hematuria
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
%dRBCs (<i>P</i>=0.0001) and UF-%sRBCs (<i>P</i>=0.0006) differed between the GN and NGN groups in patients with isolated hematuria but without proteinuria.
|
30623619 |
2019 |
|
Pancreatic carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
We hypothesized that mitotic arrest induced by AKA inhibition may sensitize PC to accelerated apoptosis by a BH3-mimetic.
|
30844579 |
2019 |